1 / 87

Myocardial Viability

A major teaching hospital of Harvard Medical School. Myocardial Viability. Thomas H. Hauser MD, MMSc, MPH, FACC Director of Nuclear Cardiology Beth Israel Deaconess Medical Center Instructor in Medicine Harvard Medical School Boston, MA. Outline. SPECT PET CMR. Imaging Protocol.

kanan
Télécharger la présentation

Myocardial Viability

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A major teaching hospital of Harvard Medical School Myocardial Viability Thomas H. Hauser MD, MMSc, MPH, FACC Director of Nuclear Cardiology Beth Israel Deaconess Medical Center Instructor in Medicine Harvard Medical School Boston, MA

  2. Outline • SPECT • PET • CMR

  3. Imaging Protocol • Stress: Prone 99mTc-Sestamibi • Rest: Prone 201Tl

  4. Case 1 Rest Stress

  5. Slices

  6. Gated Slices

  7. Gated Slices: New Window

  8. QGS Results

  9. Clinical Data • 58 year-old man with diabetes, hypertension, chronic renal insufficiency, tobacco use, prior heroin abuse and liver transplantation two years ago due to hepatitides B and C. • One week prior to admission he was admitted to another hospital with community acquired pneumonia. He was discharged two days prior to admission. • He presented on the day of admission with chest pain for 12 hours. In the ER he was noted to have anterior ST elevation.

  10. Cardiac Catheterization

  11. Cardiac Catheterization

  12. Cardiac Catheterization

  13. Cardiac Catheterization

  14. Cardiac Catheterization

  15. Clinical Data • He was referred for surgical revascularization. The surgical team requested evaluation of myocardial viability given his delayed presentation and the concern for limited myocardial salvage.

  16. Stress Protocol • Dobutamine at 5 mcg/kg/min was infused for 21 minutes. • HR 64  66 • SBP 124  134 • No symptoms • No ECG changes

  17. Baseline ECG

  18. Clinical Data Should our patient be revascularized?

  19. Dysfunctional but Viable Myocardium LVEF 32% LVEF 54% Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine: the epinephrine ventriculogram. Circulation 1974;49:1063-1071

  20. Dysfunctional but Viable Myocardium • Hibernating • Chronic ischemia or repetitive stunning • Ultrastructural changes that result in • Disassembly of contractile apparatus • Recovery in weeks or months after revascularization • Stunned • Acute ischemia • No ultrastructural changes • Recovery in minutes to days after revascularization

  21. CABG in Patients with LV Dysfunction Chareonthaitawee et al, JACC 2005;46:567

  22. Importance of Viable Myocardium J Am Coll Cardiol 2002;39:1151

  23. Evaluation of Viability Chareonthaitawee et al, JACC 2005;46:567

  24. Nuclear Techniques • SPECT • 201Tl • 99mTc • 123I Fatty Acids • PET Agents • PET • 18FDG • 11C Acetate

  25. SPECT • 201Tl most commonly used • Several protocols for use • Stress – redistribution • Rest – redistribution • Usually imaged 4 to 24 hours after initial injection • With or without reinjection • Usually at 4 hours • Perfusion tracer initially • Ischemia is a sign of viability • Membrane integrity tracer in the late phase • K analog • Assesses integrity of membrane and Na-K-ATPase

  26. SPECT • 99mTc also helpful • Stress – rest protocol • Perfusion tracer • Ischemia is a sign of viability • Membrane integrity tracer • Trapped by active mitochondria • PET agents act as with PET imaging

  27. 201Tl Uptake and Recovery of Function Perrone-Filardi P, Pace L, Pratarto M, et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease. Circulation. 1995;91:2556-2565.

  28. Comparison of 201Tl and 99mTc Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation. 1994;89:2552-2561.

  29. PET • All PET agents (18FDG, 11C acetate) assess cardiac energy metabolism. • 18FDG imaging assesses glucose metabolism • Ischemic myocardium generally favors glucose utilization • 11C acetate imaging assesses lipid metabolism

  30. Imaging Goal: High Quality Images

  31. Abnormal?

  32. Poor Image Quality

  33. Importance of Good Patient Preparation • In the assessment of myocardial viability, the quality and utility of the images is highly dependent on appropriate patient preparation • Inadequate patient preparation can lead to spurious results or images with no diagnostic value

  34. Myocardial Energy Metabolism • Cardiac myocytes are continuously active • Require efficient use of energy resources • Require continual repletion of energy substrates • Faced with varying levels in supply • Flexibility in substrate use

  35. Anaerobic Metabolism • Inefficient • Each glucose molecule yields two ATP • Requires glucose • Does not require oxygen • Lactate is the waste product Based on Autumn Cuellar (Bioengineering Institute, University of Auckland)

  36. Aerobic Metabolism • Efficient • Citric acid cycle produces abundant ATP • Can function with multiple substrates • Requires oxygen • Water and CO2 are the waste products Based on Autumn Cuellar (Bioengineering Institute, University of Auckland)

  37. Myocardial Energy Metabolism ketone bodies amino acids Based on Autumn Cuellar (Bioengineering Institute, University of Auckland)

  38. Myocardial Energy Metabolism ketone bodies amino acids Based on Autumn Cuellar (Bioengineering Institute, University of Auckland)

  39. Glucose Handling • Largely determined by the availability of glucose in the blood stream • Insulin is the major regulatory hormone

  40. Glucagon Glucose Handling: Fasting

  41. Glucose use Gluconeogenesis Glycogen FFA Glucagon Glucose Handling: Fasting

  42. Glucose Handling: Fed

  43. Glucose use Gluconeogenesis Glycogen Fat storage Glucose Handling: Fed

  44. Glucose Handling: Fed Glucose use Gluconeogenesis Glycogen Fat storage

  45. Glucose Handling: Diabetes (1)

  46. Glucose use Gluconeogenesis Glycogen FFA Glucose Handling: Diabetes (1)

  47. Glucose Handling: Diabetes (2)

  48. Glucose use Gluconeogenesis Glycogen FFA Glucose Handling: Diabetes (2)

  49. Glucose Handling • In normal patients, feeding causes a rise in glucose and insulin that restores glucose balance • Uptake of glucose in peripheral tissues • HEART • In type 1 diabetics, feeding causes a rise in glucose while insulin remains low/absent • Continued gluconeogenesis and glucose conservation • In type 2 diabetics, feeding causes a rise in glucose and insulin but peripheral tissues are resistant to the action of insulin • Continued gluconeogenesis and glucose conservation

  50. FDG FDG: C6H11O5 Glucose: C6H12O6

More Related